Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
Sponsor: Massachusetts General Hospital
Listed as NCT01438073, this PHASE1 trial focuses on Agonadism and Healthy Postmenopausal Women and remains completed. Sponsored by Massachusetts General Hospital, it has been updated 15 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
▶ Show 10 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jan 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
Jul 2019 — Jan 2020 [monthly]
Recruiting PHASE1
-
Jan 2019 — Jul 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — May 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .